patiets with malignant dises and is most common in carcinoma of the lung, breast, kKiney and in haematological malignancies (particularly myeloma) (Muggia, 1990) . It is usually associated with advanced disease and often, but not always, with bone metastases (Mundy, 1990) . The symptoms associated with TIH inclue nausea, weakness, fatigue, lethargy, constipation and confusion. Left untreated, TIH may progress to coma and death (Ritch, 1990) . Treatment of T in the past has included forced diuresis, corticosteroids, phosphates, mithramycin, calcitonin and gallium nitrate. Each of these treatments has limitations and potential for toxicity (Ritch, 1990) .
The bisphosphonates are now well established as the treatment of choice for TIH, and their role in controlling the symptoms of TIH is also well documented (Ralston et al., 1985) . Their mode of action is not completely understood, but the end result is an inhibition of bone resorption via disruption of the normal osteoclast activity in bone (Coleman and Purohit, 1993) . Side-effects are rare and include transient pyrexia, GI Survival curves were constructed using the Kaplan-Meier product limit method. They were compared using the logrankr test Multivariate analysis was performed using Cox's regression. The multivariate analysis gives an indication of prognosis following TllH, taling into account factors which are kInown at the time of the episode of TmH. The achievement of normocacaemia is time dependent, i.e. the longer the patient survives and is followed up, the more likely he or she is to achieve normocaemia. It is therefore not possible to know soon after the episode of TmH whether a patient will become normocakaemic of not. Succe or failure in achieving normocacaemia was therefore not included in the multivariate analysis. Similarly, both the total dose of APD received and the total number of courses of radiotherapy given are time dependent and were therefore not included in the survival analysis.
Redbt
One hundred and fourteen patients were identfied (44 men and 70 women) with a median age of 58 years (range 31-83). Tumour types are listed in Table I , with breast, lung and renal cell tumours being most common. The median time from original diais of malignancy to the development of TIH was 16 months (range 0-271 months). Five patients had previously recived bisphosphonates for treatment of bone pain before developing TIH. The median serum calcium at time of first detection of (Ralston et al., 1990) and in a dose-finding study of APD (Ralston et al., 1988 This study is consistent with the above series and confirms the dismal prognosis of TIH. The overall survival of all patients treated with APD was less than 2 months. Even for those patients who could still receive specific anti-cancer therapy (i.e. had not exhausted all oncological therapeutic options) the median survival was less than 3 months. The availability of anti-cancer therapy was a signiicant prognostic factor however. Even though the median survival was short, a small number of patients in this group survived for many months (30% at 6 months, 20% at 1 year).
Those patients presenting with TllH who were considered too unwell to receive APD were not taken into account in this study. The true survival figures might therefore be even worse than indicated. On the other hand, this may be balned by those patients with only miklly elevated levels of serm calcium who may have been asymptomatic and therefore not given APD, e.g. before chemotherapy to which they responded.
Failure to achieve normocalcaemia following treatment with APD was the only other significnt poor prognostic factor with respect to survival. Moreover, the difference (Harris, 1992) . Similarly, sex and tumour type were not significant. It was of interest in this study that neither time from diagnosis to TIH (i.e. greater or less than 18 months from original tumour diagnosis) nor the level of serum calcium at time of treatment was relevant. There is still controversy as to the correct dose of bisphosphonate necessary to treat TIH. A dose of 30 mg of APD is considered suboptimal by many but did not appear to affect survival adversely in this study, although the success of palliation of symptoms with this dose was not measured. Radiotherapy offers excellent palliation for the pain associated with bone metastases (Hoskin, 1988) but is not a systemic therapy and would therefore not be expected to affect survival. The multivariate analysis showed this to be beneficial however. This might reflect the fact that only those patients surviving the initial episode would live long enough to receive radiotherapy.
In summary, this study shows that for patients who have not exhausted all oncological therapeutic possibilities (i.e. still have a chance of responding to systemic anti-cancer therapy), treatment with APD can prolong life as well as palliate the symptoms of hypercalaemia. Although the median survival was poor in this group, a few patients will survive for many months, especially those with responsive tumours, e.g. breast cancer.
The dismal prognosis of this condition, however, particularly in those patients in whom no further specific anticancer treatment is possible, supports the contention that the primary aim of treatment of TIH should be to achieve symptom control rather than to improve survival. Although the symptoms commonly associated with hypercalcaemia, i.e. thirst, nausea, lethargy, malaise, drowsiness, constipation and confusion, are often very distressing and should be treated, the benefit of treating TIH in a patient in whom no further anti-cancer therapy is possible and who presents with no symptoms must be questioned in the light of these survival data.
